GPCRs-Targeted Drug Discovery Summit Leaderboard
  • Friday, May 1, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Obesity & Weight Loss Drug Development Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 7

Author

Pharma Journalist 8769 posts 0 comments

Otsuka to Acquire Transcend in $1.2 Billion Deal

Mar 31, 2026
Otsuka Pharmaceutical has announced plans to acquire Transcend Therapeutics in a deal valued at up to $1.225 billion, strengthening its presence in the neuropsychiatric treatment space…
Read More...

FDA Approves Lifyorli for Platinum-Resistant Ovarian Cancer

Mar 26, 2026
Corcept Therapeutics has announced that the U.S. Food and Drug Administration has approved Lifyorli (relacorilant) in combination with nab-paclitaxel for the treatment of adults with…
Read More...

Tempus, Daiichi Sankyo Partner to Advance AI-Driven ADC Development

Mar 26, 2026
Tempus AI has announced a strategic collaboration with Daiichi Sankyo to accelerate the clinical development of antibody-drug conjugates (ADCs) in oncology, highlighting the growing…
Read More...

Cognito, Ochsner Launch Brain Health Collaboratory Initiative

Mar 26, 2026
Cognito Therapeutics has partnered with Ochsner Health to establish a new Brain Health Collaboratory aimed at advancing innovative approaches to treating cognitive decline and…
Read More...

Merck to Acquire Terns in $6.7 Billion Deal

Mar 26, 2026
Merck & Co.—known as MSD outside North America—has announced a definitive agreement to acquire Terns Pharmaceuticals in a deal valued at approximately $6.7 billion, strengthening…
Read More...

UCB Wins EMA Support for Zilucoplan Pre-Filled Pen

Mar 26, 2026
UCB has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), recommending an update to the marketing authorization for…
Read More...

Japan Approves Dupixent for Bullous Pemphigoid Treatment

Mar 25, 2026
Japan’s Ministry of Health, Labour and Welfare has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of adults with moderate-to-severe bullous…
Read More...

Gilead to Acquire Ouro Medicines to Expand Autoimmune Portfolio

Mar 25, 2026
Gilead Sciences has announced a definitive agreement to acquire Ouro Medicines, a privately held firm focused on developing T cell engager therapies for autoimmune diseases. The move…
Read More...

Merck, Quotient Partner to Discover New IBD Drug Targets

Mar 25, 2026
Quotient Therapeutics has entered a multi-year research collaboration with Merck & Co.—known as MSD outside the United States and Canada—to identify new drug targets for…
Read More...

Viz.ai, Alnylam Partner to Improve Amyloidosis Diagnosis

Mar 25, 2026
Viz.ai has announced a strategic partnership with Alnylam Pharmaceuticals aimed at improving the early detection and diagnosis of cardiac amyloidosis, a serious and often underdiagnosed…
Read More...
Prev Next
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
GPCRs-Targeted Drug Discovery Summit
5th World ADC Summit South Korea
Extrahepatic Lipid-Based Nanoparticles Delivery Summit
World TPD & Induced Proximity Summit South Korea
Measuring Patient Engagement Summit
Investigative & Preclinical Toxicology Summit 2026
LEAP HR: Life Sciences West
Oligonucleotides for CNS Summit
R&D Procurement & Sourcing in Pharma Summit
In Vivo Cell Engineering & Gene Editing Summit
PFS & Injectable Drug Delivery West Coast
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
World Bispecific & T-Cell Engager Summit South Korea
TCR-Based Therapies Summit
PFS & Injectable Drug Devices East Coast
5th ADC Analytical Development Summit
Nasal Formulation & Delivery Summit
Peptide-Based Therapeutics Summit 2026
ALS Drug Development Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Gilead Completes $7.8 Billion Arcellx Acquisition Deal
  • EU Approves Rhapsido for Chronic Hives Treatment
  • Lilly to Acquire Ajax in $2.3 Billion Deal
  • Saphnelo Pen Approval Expands Lupus Treatment Access
  • BioMarin Completes $4.8 Billion Amicus Acquisition

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

Turning Biophysical Data into Confident Drug Discovery…

Targeted LNP Delivery Beyond the Liver: The Challenges…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.